SCHEMBL844403

SCHEMBL844403

N#Cc1ccc2[nH]c3c(ccc4cc[nH]c43)c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 1/20 0.62
AR P10275 1/20 0.54
IMPDH2 P12268 1/20 0.53
IMPDH1 P20839 1/20 0.53
CHUK O15111 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.40
RIPK1 Q13546 1/20 0.38
CHEK1 O14757 1/20 0.38
PARP1 P09874 1/20 0.37
FASN P49327 1/20 0.36
CCNE2 O96020 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844356 0.77 PIM3 (0.68) PIM3CHUKRIPK1CHEK1CCNE2
SCHEMBL844646 0.77 PIM3 (1.00) PIM3ARCHUKCHEK1CCNE2
SCHEMBL31060188 0.77 PIM3 (1.00) PIM3ARCHUKCHEK1CCNE2
SCHEMBL30545930 0.75 CHUK (0.68) ARIMPDH2IMPDH1CHUKMEN1
SCHEMBL606784 0.75 CHUK (0.68) ARIMPDH2IMPDH1CHUKMEN1
SCHEMBL29402283 0.75 CHUK (0.68) ARIMPDH2IMPDH1CHUKMEN1
SCHEMBL844971 0.75 PIM3 (0.64) PIM3CHUKCCNE2CDK4CCND1
SCHEMBL844942 0.75 PIM3 (0.64) PIM3CHUKCCNE2CDK4CCND1
SCHEMBL844580 0.73 PIM3 (0.62) PIM3RIPK1CCNE2CDK4CCND1
SCHEMBL12234734 0.73 PIM3 (0.62) PIM3MEN1KMT2ACCNE2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481586-B2 Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-07-09 US claimed
EP-2326649-B1 NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS CENTRE NAT RECH SCIENT (FR) 2012-03-28 EP claimed
US-20110263669-A1 Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) 2011-10-27 US claimed
US-8481586-B2 Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-07-09 US disclosed
US-8481586-B2 Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-07-09 US disclosed
EP-2326649-B1 NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS CENTRE NAT RECH SCIENT (FR) 2012-03-28 EP disclosed
US-20110263669-A1 Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) 2011-10-27 US disclosed
US-20110263669-A1 Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) 2011-10-27 US disclosed
WO-2010000978-A1 NOVEL PYRROLO [2,3-A] CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263669-A1 Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors PIM3, PIM1, PIM2 PIM3 1/4885AR 4070/4885IMPDH2 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.